OU Researchers Develop Novel, Non-Invasive Cancer Therapy Using Targeted Single-Walled Carbon Nanotubes
Norman, Okla.—A staggering 1.7 million persons
in the United States will be diagnosed with cancer in 2016, with 600,000 cases
ending in death. University of Oklahoma researchers have
collaborated to design a novel,
non-invasive cancer therapy that could eliminate tumors without affecting the
healthy cells in the body.
The cancer
therapy targets specific cancer cells using single-walled carbon nanotubes that
bind directly to the tumor, then are heated with near-infrared light. The OU photothermal therapy is most effective
against shallow or surface tumors in breast, bladder, esophageal and melanoma
cancers, without the adverse side effects of chemotherapy, radiation or surgery.
The therapy
was created by Roger G. Harrison, Jr. and Daniel E. Resasco, professors in the
School of Chemical, Biological and Materials Engineering, Gallogly College of
Engineering. Harrison is also affiliated with the Stephenson School of Biomedical
Engineering. Harrison’s expertise is protein
design, production and purification, while Resasco focuses on nanostructured
materials based on single-walled carbon nanotubes.
“Single-walled
carbon nanotubes are unique in that they strongly absorb near-infrared light in
very narrow, but tunable, wavelength ranges, while biological systems have very
low levels of absorption of near-infrared light,” said Harrison. “The targeting of single-walled carbon
nanotubes to tumors and subsequent localized application of near-infrared light
allows the selective elimination of tumors.”
“Very few
groups around the world are able to synthesize nanotubes which absorb light in
a narrow range of wavelength,” said Resasco.
“We have a unique method of synthesis that produces single-wall
nanotubes with a narrow distribution of diameters and carbon atom arrangements,
which causes this selective light absorption in the near-infrared spectrum.”
The new OU photothermal
therapy consists of single-walled carbon nanotubes of tailored absorption
wavelength injected into the blood stream where proteins on the nanotubes
selectively bind to blood vessels that supply a tumor. Within 24 hours, a laser light is applied to
the tumor causing the nanotubes to heat up, which causes the tumor to heat and
be eliminated. The photothermal therapy
has been tested and proven in the laboratory.
The OU
researchers already have one U.S. patent for this technology, and a second
patent is nearing issuance. The OU Office
of Technology Development and the inventors are actively seeking licensees for
this novel therapy to move to clinical trials.
For more information about this cancer therapy, contact Andrew Pollock, director
of Business Development, at arpollock@ou.edu.
# # #
Support for
this research was provided by the U.S. Department of Energy under grant numbers
DE-FG02-06ER64239 and DOE/EPSCOR DE SC0004600.
Contact: Jana Smith, Director
Strategic Communications for R&D
University of Oklahoma